Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioCorRx Inc.BICX · Entity 8179 | Director · 10% owner | January 02, 2024 | April 05, 2024 |
| RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.OPP · Entity 6374 | Exec Comm Mbr: OPP Subadviser | September 27, 2016 | September 27, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioCorRx Inc.
Report date January 02, 2024 · Filed April 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001SEC Table I · non-derivative | Direct | 237,858 |
Ending reported balance
After 2024-03-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-01-02 · Grant · Acquired 6,173 · Balance 232,292 F1: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81. Row 2 · 2024-03-28 · Grant · Acquired 5,566 · Balance 237,858 F2: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81.
F2: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90.
RiverNorth/DoubleLine Strategic Opportunity Fund, Inc.
Report date September 27, 2016 · Filed September 27, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2016-09-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 28, 2024 Filed Apr 5, 2024 20:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001895 · form4.xml · nonDerivative · entry 2 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,858 F2 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.90. Read SEC document |
| January 02, 2024 Filed Apr 5, 2024 20:19 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 6,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-001895 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,292 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.81. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 19:06 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,858 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-007312 · primary_doc.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,119 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.75. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 12:27 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 5 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,261 F5 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. Read SEC document |
| March 31, 2023 Filed Jul 6, 2023 12:27 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 4 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,370 F4 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. Read SEC document |
| March 29, 2023 Filed Jul 6, 2023 12:27 UTC | BioCorRx Inc. BICX · Entity 8179 | PurchaseCommon Stock, par value $0.001 | 171,296 | $1.75 | $299,768.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 3 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 217,546 F3 · kind: These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. F3 · ownership.nature: These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. Read SEC document |
| December 30, 2022 Filed Jul 6, 2023 12:27 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 2 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,250 F2 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. Read SEC document |
| September 30, 2022 Filed Jul 6, 2023 12:27 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005033 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,931 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. Read SEC document |
| June 30, 2022 Filed Jul 8, 2022 10:02 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 2,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004886 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,481 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39. Read SEC document |
| March 31, 2022 Filed Apr 5, 2022 16:04 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002052 · form4.xml · nonDerivative · entry 2 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,797 F2 · kind: These shares were issued to Mr. Galligan pursuant to the Director Agreement referenced in footnote 1. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55. Read SEC document |
| December 31, 2021 Filed Apr 5, 2022 16:04 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002052 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,389 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38. Read SEC document |
| September 30, 2021 Filed Oct 26, 2021 21:35 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,381 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-007587 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,248 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62. Read SEC document |
| June 30, 2021 Filed Jul 7, 2021 00:23 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-004469 · form4.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,867 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13. Read SEC document |
| March 31, 2021 Filed Apr 5, 2021 19:43 UTC | BioCorRx Inc. BICX · Entity 8179 | GrantCommon Stock, par value $0.001 | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-21-002030 · primary_doc.xml · nonDerivative · entry 1 GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,657 F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.